TY - JOUR
T1 - Predicting response to TNF antagonists in rheumatoid arthritis
T2 - The promise of pharmacogenetics research using clinical registries
AU - Greenberg, Jeffrey D.
AU - Ostrer, Harry
PY - 2007
Y1 - 2007
N2 - Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.
AB - Despite the demonstrated efficacy of three different classes of biologic response modifiers (BRMs) for the treatment of rheumatoid arthritis (RA), there are currently no clinical predictors or biomarkers that can rationally guide physicians in the selection of BRMs for individual patients. One promising area of translational research for patients with RA is the field of pharmacogenetics. In the absence of industry-sponsored pharmacogenetic studies of BRMs, longitudinal clinical registries may represent the most promising setting for identifying genetic biomarkers. This review focuses on published pharmacogenetic studies of TNF antagonists and discusses related methodologic issues for pharmacogenetic research using clinical registries.
UR - http://www.scopus.com/inward/record.url?scp=34548452460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34548452460&partnerID=8YFLogxK
M3 - Article
C2 - 17581108
AN - SCOPUS:34548452460
SN - 1936-9719
VL - 65
SP - 139
EP - 142
JO - Bulletin of the NYU Hospital for Joint Diseases
JF - Bulletin of the NYU Hospital for Joint Diseases
IS - 2
ER -